Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, Maryland; Duke University School of Medicine, Durham, North Carolina.
Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, Maryland.
JACC Heart Fail. 2013 Jun;1(3):237-44. doi: 10.1016/j.jchf.2013.03.005. Epub 2013 Jun 3.
The goal of this study was to test the hypothesis that in recipients of cardiac resynchronization therapy defibrillators (CRT-D), conventional left bundle branch block (LBBB) diagnosis predicts better survival in women than in men.
New York Heart Association class I and II patients without LBBB do not benefit from CRT-D, and women have better survival after CRT-D than men. Separate analysis suggests that QRS duration thresholds for LBBB diagnosis differ according to sex, and conventional LBBB electrocardiographic criteria are falsely positive in men more frequently than in women.
We analyzed Medicare records from 144,642 CRT-D recipients between 2002 and 2008 that were followed up for up to 90 months. Medicare billing data were used to determine age, sex, race, and comorbidities. Hazard ratios (HRs) were calculated to assess if conventional LBBB diagnosis had different prognostic significance according to sex.
In univariate analysis, LBBB was associated with a 31% reduction in death in women (HR: 0.69 [95% confidence interval (CI): 0.67 to 0.71]) but only a 16% reduction in death in men (HR: 0.84 [95% CI: 0.82 to 0.85]). In multivariable analyses controlling for comorbidities, LBBB was associated with a 26% reduction in death in women (HR: 0.74 [95% CI: 0.71 to 0.77]) and a 15% reduction in death in men (HR: 0.85 [95% CI: 0.83 to 0.87]). A significant interaction (p < 0.0001) between sex and LBBB was seen.
LBBB diagnosis is associated with greater survival in women than in men receiving CRT-D, and this discrepancy is not explained by differences in measured comorbidities. Possible explanations for this difference include that LBBB may have different prognostic significance according to sex or that LBBB diagnosis is more often false-positive in men compared with women.
本研究旨在验证如下假设,即在接受心脏再同步治疗除颤器(CRT-D)的患者中,传统的左束支传导阻滞(LBBB)诊断在女性中的预测生存率优于男性。
纽约心脏协会(NYHA)I 级和 II 级无 LBBB 的患者不能从 CRT-D 中获益,并且女性在接受 CRT-D 后比男性的生存率更高。单独的分析表明,LBBB 诊断的 QRS 持续时间阈值因性别而异,并且传统的 LBBB 心电图标准在男性中比在女性中更常出现假阳性。
我们分析了 2002 年至 2008 年间接受 CRT-D 治疗的 144642 名 Medicare 记录患者,随访时间长达 90 个月。使用 Medicare 计费数据确定年龄、性别、种族和合并症。计算风险比(HRs)以评估传统 LBBB 诊断是否根据性别具有不同的预后意义。
在单变量分析中,LBBB 与女性死亡风险降低 31%相关(HR:0.69 [95%置信区间(CI):0.67 至 0.71]),但与男性死亡风险降低 16%相关(HR:0.84 [95% CI:0.82 至 0.85])。在多变量分析中,控制合并症后,LBBB 与女性死亡风险降低 26%相关(HR:0.74 [95% CI:0.71 至 0.77]),与男性死亡风险降低 15%相关(HR:0.85 [95% CI:0.83 至 0.87])。观察到性别与 LBBB 之间存在显著的交互作用(p < 0.0001)。
在接受 CRT-D 的女性中,LBBB 诊断与生存率的提高相关,而这一差异不能用测量的合并症差异来解释。造成这种差异的可能原因包括 LBBB 可能根据性别具有不同的预后意义,或者与女性相比,LBBB 诊断在男性中更常出现假阳性。